about
Functional data analysis in NTCP modeling: a new method to explore the radiation dose-volume effects.[Radiation therapy and immunomodulation: Focus on experimental data].[Current data on radiochemotherapy and potential of targeted therapies for cervical cancers].Novel anti-metastatic action of cidofovir mediated by inhibition of E6/E7, CXCR4 and Rho/ROCK signaling in HPV tumor cells.Phase I Dose-Escalation and Pharmacokinetic Study of Intravenous Aflibercept in Combination with Docetaxel, Cisplatin, and 5-Fluorouracil in Patients with Advanced Solid Malignancies.A phase 1 dose-escalation study of the oral histone deacetylase inhibitor abexinostat in combination with standard hypofractionated radiotherapy in advanced solid tumors.Prognostic value of tumor mutations in radically treated locally advanced non-small cell lung cancer patients.[Reirradiation of normal tissues: preclinical radiobiological data].Lung cancer stem cell: new insights on experimental models and preclinical data.Bioluminescent orthotopic mouse models of human localized non-small cell lung cancer: feasibility and identification of circulating tumour cellsCytotoxic effect of lapatinib is restricted to human papillomavirus-positive head and neck squamous cell carcinoma cell lines.Simultaneous irradiation of fibroblasts and carcinoma cells repress the secretion of soluble factors able to stimulate carcinoma cell migration.Field size dependent mapping of medical linear accelerator radiation leakage.The use of theranostic gadolinium-based nanoprobes to improve radiotherapy efficacy.From prospective biobanking to precision medicine: BIO-RAIDs - an EU study protocol in cervical cancerNormal tissues toxicities triggered by combined anti-angiogenic and radiation therapies: hurdles might be aheadDosimetric Effects of the Interfraction Variations during Whole Breast Radiotherapy: A Prospective Study.Enhancement of IUdR Radiosensitization by Low-Energy Photons Results from Increased and Persistent DNA Damage.New concepts for phase I trials: evaluating new drugs combined with radiation therapy.Tyrosine kinase inhibitor AG1024 exerts antileukaemic effects on STI571-resistant Bcr-Abl expressing cells and decreases AKT phosphorylation.Radiotherapy for localized rectal cancer.IGF-1R targeting increases the antitumor effects of DNA-damaging agents in SCLC model: an opportunity to increase the efficacy of standard therapyTreatment outcome and survival in participants of phase I oncology trials carried out from 2003 to 2006 at Institut Gustave Roussy.The multidisciplinary management of gastrointestinal cancer. Pancreatic cancer: from pathogenesis to cure.Drug insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy.The efficacy and toxicity of EGFR in the settings of radiotherapy: Focus on published clinical trials.Molecular profiling of uterine cervix carcinoma: an overview with a special focus on rationally designed target-based anticancer agents.Phase I trial evaluating the antiviral agent Cidofovir in combination with chemoradiation in cervical cancer patientsConcomitant chemo-radiotherapy in clinical trials: to promote step by step rational development.Inflammatory bowel diseases activity in patients undergoing pelvic radiation therapy.Leukocytosis and neutrophilia predict outcome in locally advanced esophageal cancer treated with definitive chemoradiation.Unravelling the biology of human papillomavirus (HPV) related tumours to enhance their radiosensitivity.Current state of knowledge regarding the use of antiangiogenic agents with radiation therapy.Radiation therapy and immunotherapy: implications for a combined cancer treatment.Combination of vascular disrupting agents and ionizing radiation.Personalized radiation therapy and biomarker-driven treatment strategies: a systematic review.Complications of thoracic radiotherapy.The use of radiotherapy for early breast cancer in woman at different ages.Increased radiosensitivity of HPV-positive head and neck cancers: Molecular basis and therapeutic perspectives.Clinical outcomes after interstitial brachytherapy for early-stage nasal squamous cell carcinoma.
P50
Q30859173-2D29A0A5-988F-42B1-9435-827F76877290Q30988478-EC299184-D3E7-4437-BEEC-25267923CDD8Q31144369-9D339DC2-BFAC-4C63-9B83-A269E567E4A6Q33422883-2A6ED26F-193A-4E12-9770-D8ECD3BE807BQ33426954-85F299F8-E431-4488-8AA4-590B7C90CCF0Q33437948-839FA33A-5283-498C-A3DA-508C1385F8F3Q33648808-051BABF4-F26C-4E4F-BA91-0D6C780E2EA2Q33667915-1DD73B49-EC81-411D-837C-3154121875ABQ33786637-99FCA933-67C3-458C-AB9A-484A5D321920Q34055939-1D96D02F-1045-4BB5-8C5F-B020504BFDC9Q35067562-FB5F49A2-ECBB-47AD-B0AE-09188300BE7BQ35551808-E55B6D7A-B8F9-4A3B-8ABB-91C3D2DE4ACCQ35559872-E864C4BC-C5C6-42C9-898F-C6DC1EBA3200Q35676729-810C20DD-5FCE-4DBD-A085-95BAE885588FQ35831356-ABA00BA1-BCF3-4B2E-9703-EA8E69419D18Q36089944-A4930AAB-37AB-4E0A-8454-985C3DAEBDE7Q36097465-E9EA5787-27C2-46E6-A324-98CF9DE53811Q36238111-3D4DFD63-4145-4C81-A7DB-AD5BE3140876Q36304022-BD9EDE73-3471-4694-B97B-AAE849ABBB47Q36695924-089B14BD-21EC-4CA6-9839-D33F982BC824Q36881968-418714AE-1C82-4D5E-BECA-36BCD54225A7Q37001172-90BB16D1-DCA1-460B-9EB7-D13F51FEB4C0Q37016543-49829D44-E0A0-4C41-8048-A12636825506Q37028521-39FF3D97-3D61-40C1-BE6A-E35B04BB5A8AQ37113427-F6248CD3-C8C4-434C-A22F-287690E9CC36Q37240451-E4C89A94-99E9-4547-B263-017155774B8EQ37267360-A4FE1818-632F-46E8-BDA5-27432B85CE21Q37295412-508AD591-5799-4D40-B2D3-E75C356F60E9Q37337661-E0D688F3-75ED-420B-B9C4-CAD0FDCCCA87Q37677512-AE8E9E69-6A20-43F6-BCC1-ECC77CE52786Q37706953-19C5E9B1-9F78-4225-8091-877848D0255DQ37736757-ABF23A2C-F151-47DB-9800-C3CDDCA14F98Q37872453-ECCFB47E-CC04-4967-B0C4-C00E1F21A67BQ38049407-DF3BD25C-8155-48A5-9551-D364048D9729Q38062100-4D76AABD-7B4A-494B-B019-FBF636A4A5D5Q38099763-7E723FAE-BE51-4641-B001-4CDFEB1D2BF5Q38131144-DFC79361-AF3B-4061-ACD3-A69BB63D6705Q38197109-0ABFA40F-81F7-4864-9DED-2CB444AA7B61Q38609955-407B8B28-1701-4ECA-A4B3-3AC09932039DQ38661664-7C857642-BCF3-429F-8E94-38FE9190E875
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Eric Deutsch
@ast
Eric Deutsch
@en
Eric Deutsch
@es
Eric Deutsch
@nl
type
label
Eric Deutsch
@ast
Eric Deutsch
@en
Eric Deutsch
@es
Eric Deutsch
@nl
prefLabel
Eric Deutsch
@ast
Eric Deutsch
@en
Eric Deutsch
@es
Eric Deutsch
@nl
P106
P1153
35350950800
P31
P496
0000-0002-8223-3697